Business
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and olderThis approval makes AGAMREE the first and only approved therapy for DMD in Canada Pratteln, Switzerland, October 3, 2025 – Santhera Pharmaceuticals (SIX: SANN) today notes that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older following Priority Review, marking the first approved treatment for th
About this update from Catalyst Pharmaceuticals, Inc.
[{"type":"image","alt":"Santhera Pharmaceuticals Holding AG","displaySize":"","headline":null,"caption":"Santhera Pharmaceuticals Holding AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":235,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/69b76b9d28605c9cb06e9f424ed2d9b3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m.yMU32TDRiiNbpVl.Y_mw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/69b76b9d28605c9cb06e9f424ed2d9b3","width":235,"height":71}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"This approval makes AGAMREE the first and only approved therapy for DMD in Canada","length":81,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":195,"olType":false},{"type":"text","content":"Pratteln, Switzerland, October 3, 2025 – Santhera Pharmaceuticals (SIX: SANN) today notes that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older following Priority Review, marking the first approved treatment for the disease in Canada. The Canadian Neuromuscular Disease registry estimates that there are more than 800 boys and young men living with DMD in Canada and coping with its debilitating symptoms.","length":495,"tagName":"p"},{"type":"text","content":"Kye Pharmaceuticals holds exclusive Canadian commercial rights to AGAMREE for the treatment of DMD and potentially other indications, following the agreement of a sub-license with Santhera’s commercialization partner Catalyst Pharmaceuticals, Inc. (“Catalyst”) in July 2024. Santhera will receive royalties on Canadian sales and these sales will also contribute towards North American sales milestones payable to Santhera from its partner Catalyst.","length":453,"tagName":"p"},{"type":"text","content":"This is the sixth independent approval a by local health authority, following positive regulatory decisions in the U.S., Europe, the UK, China and Hong Kong.","length":157,"tagName":"p"},{"type":"text","content":"About Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a rare inherited X-chromosome-linked disease, which ...